Table 2 Prior treatment
From: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Type of treatment | No. (%) |
|---|---|
Total no. of patients | 24 (100%) |
Surgery | 24 (100%) |
Immunotherapy (IFN-a) | 1 (4%) |
Chemotherapy (vindesin) | 6 (25%) |
Chemotharapy (Dacarbazine) | 2 (8%) |
Immunochemotherapy (Dacarbazine+IFN-a) | 6 (25%) |
Local radiotherapy | 4 (17%) |
Limb perfusion (melphalan+dactinomycin) | 4 (17%) |
